HOUSTON–(BUSINESS WIRE)–Nov. 4, 2004–CytoGenix Inc. (OTCBB:CYGX) announces that it has submitted a pre-Investigational New Drug (IND) brief and has initiated discussions with the

HOUSTON--(BUSINESS WIRE)--Nov. 4, 2004--CytoGenix Inc. (OTCBB:CYGX) announces that it has submitted a pre-Investigational New Drug (IND) brief and has initiated discussions with the

HOUSTON--(BUSINESS WIRE)--Nov. 4, 2004--CytoGenix Inc. (OTCBB:CYGX) announces that it has submitted a pre-Investigational New Drug (IND) brief and has initiated discussions with the
Post-Graduate Training Postdoctoral fellow, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 1989-1991. Overlapping reports were identified by comparing methods and results. Sources searched for relevant studies were the Cochrane Central Register of Controlled Trials – CENTRAL (which contains the Cochrane Eyes and Vision Group trials register), (Issue 3 2002), MEDLINE (1966 to August 2002), EMBASE (1980 to August 2002), LILACS (up to 2002), Index Medicus (1960 to 1965), Excerpta Medica Ophthalmology (1960 to 1973), reference lists of primary reports and review articles, and conference proceedings pertaining to ocular virology. The treatment with 0.1% Simplivir(TM) resulted in a reduction in the total lesion area when compared to placebo. Analyses were conducted comparing the precision of the estimated intervention effects for the different designs. Together, our results suggest that rapamycin could be used to potentiate the activity of oncolytic HSVs against difficult-to-treat human tumors or perhaps to prevent the emergence of resistant tumor cells during virotherapy. Tyring is a dermatologist and virologist who conducts research in the areas of prevention, treatment and vaccinations for a wide range of diseases and conditions.

Specialists are on hand Monday through Friday from 12:00 pm to 4:00 pm ET (9:00 am to 1:00 pm PT) to help locate trials and answer questions. Patients receiving life-long T cell-based immunosuppression have an increased risk of developing PTLD due to their inability to produce normal immunoregulatory responses. pending patent applications. SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Brain MRI scan ± Gd will be performed on subjects at entry, day 28 and day 90. Prostate biopsies performed at 24 months after completion of treatment were negative in 83 percent of Arm A patients and 79 percent of Arm B patients. Additional information about CytoGenix and its technology is found on the Web site at www.cytogenix.com.

You may also like